In an announcement that stunned scientists, the U.S. Environmental Protection Agency has cancelled grant applications for what was supposed to be a $20-million, four-year green chemistry program. The mysterious cancellation comes less than three weeks before the deadline for the proposals. The grants, which were supposed to fund four new centers, would have been a major new source of funding for green chemistry, a field that seeks to design environmentally friendly chemicals and processes that can replace toxic substances. The requests for proposals may be reissued, the EPA said. But the program’s sudden halt and uncertain future — and lack of explanation — have left scientists disheartened. “My reaction is shock that it happened and total dismay that what appeared to be a novel program was cancelled without warning or explanation,” said Eric Beckman, a chemical engineer at the University of Pittsburgh.
![]() |
| Joshua Vaughn/flickr |
| Green chemistry’s aim is to design environmentally friendly chemicals and processes that can replace toxic substances currently in use. |
By Brett Israel
Senior Editor and Staff Writer
Environmental Health News
April 10, 2012
In an announcement that stunned scientists, the U.S. Environmental Protection Agency has cancelled grant applications for what was supposed to be a $20-million, four-year green chemistry program.
The mysterious cancellation, announced on Friday, came less than three weeks before the April 25 deadline for the grant proposals.
The federal grants, which were supposed to fund four new academic centers, would have been a major new source of funding for green chemistry, a field that seeks to design environmentally friendly chemicals and processes that can replace toxic substances.
The requests for proposals may be reissued, the EPA said Monday. But the program’s sudden halt and uncertain future – and lack of explanation – have left scientists disheartened. Lab researchers had worked for months on their proposals and scientists now fear their hard work will be wasted.
“My reaction is shock that it happened and total dismay that what appeared to be a novel program was cancelled without warning or explanation,” said Eric Beckman, a chemical engineer at the University of Pittsburgh who was working on a proposal.
Terry Collins, a green chemist at Carnegie Mellon University and a pioneer in the field, said the announcement “stunned me.” Collins was on a team of green chemists and other environmental scientists that had been working for months to put together a funding proposal. West Coast institutions, including University of California, Berkeley, also were developing a proposal.
Beckman said he’d never seen such a thing happen before – a government agency pulling the plug on a request for proposals so close to its deadline – in his more than 20 years in academia.
Eric Beckman, a University of Pittsburgh chemical engineer, said he’d never seen such a thing happen before – a government agency pulling the plug on a request for proposals so close to its deadline – in his more than 20 years in academia.The $20 million in funding would be “one of the most significant sources of dedicated support for green chemistry so it is a blow to the community that the call for applications was cancelled without explanation,” said Evan Beach, a green chemist at Yale University. “Everybody was in the home stretch on writing. The preparations took several months.”
The EPA offered no reason for the last-minute cancellation.


This figure is taken from Green chemistry: state of the art through an analysis of the literature by V. Dichiarante, D. Ravelli and A. Albini. Green Chemistry Letter and Reviews Vol. 3, No. 2, June 2010, 105-113.





Researchers close in on making a natural malaria drug.
Friday, June 8th, 2012Westfall, PJ, DJ Pitera, JR Lenihan, D Eng, FX Woolard, R Regentin, T Horning, H Tsuruta, DJ Melis, A Owens, S Fickes, D Diola, KR Benjamin, JD Keasling, MD Leavell, DJ McPhee, NS Renninger, JD Newman and CJ Paddon. 2012. Production of amorphadiene in yeast, and its conversion to dihydroartemisinic acid, precursor to the antimalarial agent artemisinin. Proceedings of the National Academy of Sciences http://dx.doi.org/10.1073/pnas.1110740109.
Synopsis by Jean-Philip Lumb
A new approach to making the natural malaria drug artemisinin will increase supply and avoid the chemical steps now used to extract the drug from plants. The drug is meant to replace medicines that no longer control the malaria parasite spread by mosquitoes.
An affordable treatment for malaria is closer thanks to a process using both biology and chemistry to make artemisinin – an effective drug currently extracted from plants.
The method bypasses plants as the source of the drug. Instead, modified yeast change sugar into an advanced chemical that can be converted into artemisinin. Skirting plants decreases the cost, increases supply and avoids chemical extractions. A team of industrial and academic researchers in Berkeley, Calif., developed the biochemical route to the drug.
The process provides an alternative to traditional extractive procedures and highlights the increasing use of biotechnology in greener drug manufacturing.
Globally, the mosquito-borne infectious disease claims nearly 1 million lives per year. Health organizations estimate that 300 – 500 million people are infected on an annual basis, a population based primarily of children in Africa and Asia.
New medicines are needed because the current drugs do not work as well as they once did and controlling mosquitoes with insecticides – such as DDT – can harm the environment and human health.
Artemisinin is a desirable substitute to the widely used chloroquine-based antimalarial drugs. The Plasmodium parasite that causes malaria has become resistant to these traditional drugs.
While faster acting and more effective, artemisinin is expensive and supplies are often limited. Artemisinin is currently extracted from plants. Unfortunately, the extraction makes large-scale production too costly for countries where the drug is needed most. The methods also employ volatile organic solvents that levy a heavy environmental toll.
To overcome the current limitations in supply, a consortium of industry and academic researchers in California developed a new strain of yeast that can convert glucose into an artemisinin precursor. Standard organic chemistry practices are used for the remaining steps of the drug’s synthesis.
The combined biotechnology/synthetic chemistry approach promises to be an effective alternative to the extraction techniques currently in use. The cost is estimated as low as 300 million cures at 50 cents a treatment. A recent press-release, issued on the Amyris website, announced a partnership between Amyris, The Institute for OneWorld Health and Sanofi-Aventis to make doses of artemisinin available later this year.
Read more science at Environmental Health News.
Tags: greener process, investment in green chemistry, pharmaceutical
Posted in Commentary, Uncategorized | No Comments »